Filter Results :

Your search for Biosimilars returned 66 reports

Sort by


Global Oncology Biosimilars Market Research Report 2016

15 Oct 2016  |  Published by:  S&P Consulting
The global oncology biosimilars market will witness substantial growth over the forecast period and is expected to grow at very impressive CAGR during the forecast period. The increasing need for cost-effective treatment methodologies will aid in the stable growth of this market during the forecast ...

$ 2,800.00

Read More

Global Oncology Biosimilars Sales Market Report 2016

15 Oct 2016  |  Published by:  S&P Consulting
The global oncology biosimilars market will witness substantial growth over the forecast period and is expected to grow at very impressive CAGR during the forecast period. The increasing need for cost-effective treatment methodologies will aid in the stable growth of this market during the forecast ...

$ 3,800.00

Read More

Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise & Companies) to 2021 and Biosimilars Approved & Pipeline Analysis

03 Oct 2016  |  Published by:  iGATE Research
The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020.  With the contin...

$ 1,350.00

Read More

Humira Biosimilars Clinical Trial Insight

01 Oct 2016  |  Published by:  KuicK Research
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent p...

$ 1,500.00

Read More

Enbrel Biosimilars Clinical Trial & Opportunity Insight

01 Oct 2016  |  Published by:  KuicK Research
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilar version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 bi...

$ 1,500.00

Read More

Global mAb Biosimilars Market 2016-2020

23 Sep 2016  |  Published by:  Technavio-Infiniti Research
About BiosimilarsBiosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similari...

$ 2,500.00

Read More

Global Biosimilars And Follow-On Biologics Market Research Report 2016

06 Sep 2016  |  Published by:  9Dimen Research
2016 Global Biosimilars And Follow-On Biologics Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Biosimilars And Follow-On Biologics industry, focusing on the main regions (North America, Europe and Asia) and the main countries (Un...

$ 2,850.00

Read More

amp biosimilars AG (1YA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

24 Aug 2016  |  Published by:  GlobalData
Summaryamp biosimilars AG (amp biosimilars) is a biopharmaceutical company that develops biosimilars. Its product pipeline includes four biosimilar development projects focusing on immune disorders and cancer. The company focuses on clinical areas that include cancer, autoimmune and inflammatory dis...

$ 250.00

Read More

Global Biosimilars Market 2016-2020

01 Aug 2016  |  Published by:  Technavio-Infiniti Research
About BiosimilarsBiosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the s...

$ 2,500.00

Read More

The Future of Biosimilars 2016

01 Jul 2016  |  Published by:  FirstWord
Development activity is surging as the focus shifts to commercialisation. How will the market evolve?The race to commercialise biosimilars is on. What will it take to create a thriving market? Will payers see real cost savings? Will developers make money? What will drive uptake—and what will slow it...

$ 2,195.00

Read More

Large Cap Pharma US & EU Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future Growth

17 Mar 2016  |  Published by:  MP Advisors
Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, vaccines and consumer health care business. Onco...

$ 2,000.00
$ 1,700.00
( Save 15% )

Read More

Global Biologics and Biosimilars Industry Report 2016

12 Mar 2016  |  Published by:  QYResearch
The Global Biologics and Biosimilars Industry Report 2016 is a professional and in-depth study on the current state of the Biologics and Biosimilars industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structu...

$ 2,800.00

Read More

Global Oncology Biosimilars Market 2016-2020

17 Feb 2016  |  Published by:  Technavio-Infiniti Research
About Oncology BiosimilarsCancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practic...

$ 3,000.00

Read More

US Biosimilars Market Opportunity & Clinical Pipeline Analysis

02 Feb 2016  |  Published by:  KuicK Research
Pharmaceutical companies benefited from the revolution in biotechnology that hit US market in 1980’s. Some of the blockbuster biologics have been introduced in market helping pharmaceutical companies to occupy major market shares. Their presence could be felt in every disease segment as they were im...

$ 2,400.00

Read More

Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

01 Feb 2016  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence report titled „PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors“ provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor for the treatment of osteoporosis or of hypopara...

$ 212.26

Read More
Total 66 records.